Key TakeawaysGLP-1 drugs might lower the risk of dangerous blood clots and death among people with autoimmune diseasesPeople taking GLP-1 drugs were 44% less likely to dieThey also had a lower risk of blood clots in their lungs or causing a stroke.WEDNESDAY, June 17, 2026 (HealthDay News) People with an autoimmune disease and obesity might lower their risk of dangerous blood clots and death by taking Ozempic or Zepbound, a new study says.Autoimmune diseases like celiac disease, vitiligo, psoriasis or rheumatoid arthritis increase the risk of severe heath emergencies because they cause inflammation and malfunctioning immune responses, researchers said.But GLP-1 medications might be able to counter that risk, researchers reported recently in the Journal of the American Heart Association.Overall, peoples risk of death was cut by nearly half if they were taking a GLP-1 drug, the study found.In this real-world analysis, we found a consistent signal toward fewer serious complications including blood clots and lower mortality among patients treated with GLP-1 receptor agonists, senior researcher Dr
Although classical antioxidant drugs failed in clinical trials against neurodegenerative disorders 28 , mito GCL, by acting as a persistent antioxidant source for mitochondria, may represent a new gene therapy strategy to improve the transient efficacy of the formers
Ongoing clinical trials are exploring its efficacy and safety, positioning it as a promising option for patients with complex metabolic conditions
Meta-analytic procedures for social science research
The procedure is performed by qualified medical personnel, who monitor the patient and adjust the infusion flow to ensure safe and effective administration
